1-(2,3-二氢-1,4-苯并二恶烷-2-基)乙酮 | 1011-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 1-(2,3-二氢-1,4-苯并二恶烷-2-基)乙酮
• 中文别名: 1-(2,3-二氢-1,4-苯并二噁英-2-基)-1-乙酮；1-(2,3-二氢-1,4-苯并二噁英-2-基)乙烯酮
• 英文名称: 2-acetyl-1,4-benzodioxane
• 英文别名: 2-acetylbenzodioxane；2-Acetyl-1,4-benzodioxan；2-Acetyl-1,4-benzdioxin；1-(2,3-Dihydro-1,4-benzodioxin-2-yl)ethanone；1-(2,3-dihydro-1,4-benzodioxin-3-yl)ethanone
• CAS: 1011-48-9
• 化学式: C₁₀H₁₀O₃
• mdl: MFCD00457680
• 分子量: 178.188
• InChiKey: KVCWAZWJLMNADA-UHFFFAOYSA-N

物化性质

• 熔点：
  34-35 °C(Solv: water (7732-18-5); methanol (67-56-1))
• 沸点：
  89-90 °C(Press: 0.3 Torr)
• 密度：
  1.191±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 危险标志：
  GHS07
• 危险性描述：
  H302
• 储存条件：
  应存于室温、密封且干燥的环境中。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1-(2,3-Dihydro-1,4-Benzodioxin-2-Yl)Ethanone
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 178,19 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
1-(2,3-Dihydro-1,4-Benzodioxin-2-Yl)Ethanone
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
1-(2,3-Dihydro-1,4-Benzodioxin-2-Yl)Ethanone
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1-(2,3-二氢-1,4-苯并二恶烷-2-基)乙酮 在 盐酸 、 lithium aluminium tetrahydride 、 溴 、 calcium carbonate 、 sodium hydroxide 作用下， 以 吡啶 、 乙醚 、 乙醇 、 正己烷 、 水 、 苯 为溶剂， 反应 32.67h， 生成 4-(1,4-benzodioxan-2-yl)-N-[(1,4-benzodioxan-2-yl)methyl]thiazol-2-amine hydrochloride
  参考文献：
  名称：

  Synthesis and biologic properties of new thiazolylbenzodioxane derivatives

  摘要：

  Reaction of 4-(1,4-benzodioxan-2-yl)thiazol-2-amine with acid chlorides afforded N-substituted amides which further were reduced into the corresponding amines. A new method was developed of preparation of 2-acetyl-1,4-benzodioxane, the initial compound in the synthesis of thiazolylbenzodioxane and numerous derivatives of this series. The adreno- and sympatholytic as well as antihypoxic effect of the obtained biheterocyclic 1,4-benzodioxane derivatives were investigated.

  DOI：

  10.1134/s1070428016020159
• 作为产物：
  描述：

  2,3-二氢苯并[1,4]二恶烷-2-甲腈 、 碘甲烷 在 碘 、 magnesium 作用下， 以 乙醚 、 苯 为溶剂， 反应 7.0h， 以47%的产率得到1-(2,3-二氢-1,4-苯并二恶烷-2-基)乙酮
  参考文献：
  名称：

  Synthesis and biologic properties of new thiazolylbenzodioxane derivatives

  摘要：

  Reaction of 4-(1,4-benzodioxan-2-yl)thiazol-2-amine with acid chlorides afforded N-substituted amides which further were reduced into the corresponding amines. A new method was developed of preparation of 2-acetyl-1,4-benzodioxane, the initial compound in the synthesis of thiazolylbenzodioxane and numerous derivatives of this series. The adreno- and sympatholytic as well as antihypoxic effect of the obtained biheterocyclic 1,4-benzodioxane derivatives were investigated.

  DOI：

  10.1134/s1070428016020159

文献信息

• [EN] NOVEL CYCLIC PHENOXY COMPOUNDS AND IMPROVED TREATMENTS FOR CARDIAC AND CARDIOVASCULAR DISEASE<br/>[FR] NOUVEAUX COMPOSÉS PHÉNOXY CYCLIQUES ET TRAITEMENTS AMÉLIORÉS POUR UNE MALADIE CARDIAQUE ET CARDIOVASCULAIRE
  申请人：UNIV NOTTINGHAM

  公开号：WO2013121209A1

  公开（公告）日：2013-08-22

  A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: (Formula (I)) wherein either Q1, CR6a and optionally R6b together form a cyclic moiety wherein: Q1 is selected from C1-2 alkylene, C1-2 alkenylene, OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo; R6a is a single bond and R6b is H; or R6a and R6b together form a double bond; and Q2 and Q3 are independently selected from H, R1 and R2; or Q2 and Q3 together form a cyclic moiety in which one of Q2 and Q3 is a cyclic moiety selected from OC1 alkylene and OC1 alkenylene moieties optionally substituted by oxo or a group R5 as hereinbelow defined for R2 and the other of Q2 and Q3 is a cyclic moiety selected from C1-2 alkylene, C1-2 alkenylene and OC1 alkylene optionally substituted by oxo; R6a and R6b are each H or a cyclic moiety as defined above; and Q1 is selected from H, R1 and R2 and a cyclic moiety as defined above; and R1-4 are H or substituents; Z is selected from linear C2-3 alkylene; X3 is NH; R7-9 are H or substituents; their preparation and novel intermediates, compositions thereof and their use in the prevention or treatment of cardiac and cardiovascular disease and methods for the treatment thereof.

  化学式I的化合物，及其在游离形式或盐形式中的药学上可接受的盐或盐和生理水解衍生物：（化学式（I））其中Q1，CR6a和可选的R6b共同形成一个环状基团，其中：Q1选自C1-2烷基，C1-2烯基，OC1烷基和OC1烯基基团，可选择地被氧代取代；R6a是一个单键，R6b是H；或者R6a和R6b共同形成一个双键；Q2和Q3分别选自H，R1和R2；或者Q2和Q3共同形成一个环状基团，在该环状基团中，Q2和Q3中的一个是选自OC1烷基和OC1烯基基团，可选择地被氧代取代或由下文定义为R2的基团R5的环状基团，而另一个是选自C1-2烷基，C1-2烯基和OC1烷基，可选择地被氧代取代；R6a和R6b分别为H或如上定义的环状基团；Q1选自H，R1和R2以及如上定义的环状基团；R1-4为H或取代基；Z选自线性C2-3烷基；X3为NH；R7-9为H或取代基；它们的制备和新颖中间体，其组成物及其在心脏和心血管疾病的预防或治疗中的用途以及治疗方法。
• Novel Cyclic Phenoxy Compounds and Improved Treatments for Cardiac and Cardiovascular Disease
  申请人：University of Nottingham

  公开号：US20150051270A1

  公开（公告）日：2015-02-19

  A compound of formula I, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein either Q 1 , CR 6a and optionally R 6b together form a cyclic moiety wherein: Q 1 is selected from C 1-2 alkylene, C 1-2 alkenylene, OC 1 alkylene and OC 1 alkenylene moieties optionally substituted by oxo; R 6a is a single bond and R 6b is H; or R 6a and R 6b together form a double bond; and Q 2 and Q 3 are independently selected from H, R 1 and R 2 ; or Q 2 and Q 3 together form a cyclic moiety in which one of Q 2 and Q 3 is a cyclic moiety selected from OC 1 alkylene and OC 1 alkenylene moieties optionally substituted by oxo or a group R 5 as here in below defined for R 2 and the other of Q 2 and Q 3 is a cyclic moiety selected from C 1-2 alkylene, C 1-2 alkenylene and OC 1 alkylene optionally substituted by oxo; R 6a and R 6b are each H or a cyclic moiety as defined above; and Q 1 is selected from H, R 1 and R 2 and a cyclic moiety as defined above; and R 1-4 are H or substituents; Z is selected from linear C 2-3 alkylene; X 3 is NH; R 7-9 are H or substituents; their preparation and novel intermediates, compositions thereof and their use in the prevention or treatment of cardiac and cardiovascular disease and methods for the treatment thereof.

  化学式I的化合物，及其在自由形式或盐形式中的药用可接受盐或盐和生理可水解衍生物： 其中 Q 1 ，CR 6a 和可选的R 6b 共同形成一个环状基团，其中： Q 1 选自C 1-2 烷基，C 1-2 烯基，OC 1 烷基和OC 1 烯基基团，可选择地被氧代取代； R 6a 是一个单键，R 6b 是H；或 R 6a 和R 6b 共同形成一个双键；和 Q 2 和Q 3 分别选自H，R 1 和R 2 ； 或Q 2 和Q 3 共同形成一个环状基团，在该环状基团中，Q 2 和Q 3 中的一个是选自OC 1 烷基和OC 1 烯基基团，可选择地被氧代取代或一个R 5 基团的环状基团，如下所定义的R 2 ，而另一个是选自C 1-2 烷基，C 1-2 烯基和OC 1 烷基，可选择地被氧代取代； R 6a 和R 6b 分别为H或如上定义的环状基团；和 Q 1 选自H，R 1 和R 2 以及如上定义的环状基团； 和R 1-4 为H或取代基； Z选自线性C 2-3 烷基； X 3 为NH； R 7-9 为H或取代基；它们的制备和新颖中间体，其组合物及其在预防或治疗心脏和心血管疾病中的使用以及治疗方法。
• Ring opening and ring-chain tautomerism in 2-carbalkoxy- and 2-acyl-2,3-dihydro-1,4-benzodioxins
  作者：Vittorio Rosnati、Aldo Salimbeni

  DOI：10.1016/s0040-4020(01)87297-5

  日期：1986.1

  1-chloro-2-(diethylamino)ethane partial ring cleavage occurred, while the tautomerism was evidenced. The esters were easily converted into mixtures of the corresponding lactones 6a-c and acids 7a-c by the action of NaH in DMSO. Ketones 2a and 2b were stable in the K2CO3/acetone system, but ring-chain tautomerism was shown to be at work in the case of 2b and 2c, while the latter also underwent ring cleavage. In the

  研究了苯二恶英酯1a-c和酮2a-c在K 2 CO 3在丙酮中和NaH在DMSO中的行为。在酚类中间体或产物的清除剂存在下也进行了实验。在丙酮酸钾的作用下，该酯没有开环，并且不存在环链互变异构。然而，在1-氯-2-（二乙基氨基）乙烷存在下，部分环发生裂解，而互变异构现象得到了证明。通过在DMSO中的NaH的作用，酯容易地转化为相应的内酯6a-c和酸7a-c的混合物。酮2a和2b在K 2 CO 3中稳定/丙酮系统，但在2b和2c的情况下显示环链互变异构起作用，而后者也经历了环裂解。在相同的系统中，但是在存在烷基化剂的情况下，这三个酮很容易开环。
• Anti-hypertensive benzodioxan derivatives
  申请人：Bouchara; Emile

  公开号：US04432984A1

  公开（公告）日：1984-02-21

  This invention relates to benzodioxanylalkylpiperidines, to processes for producing them and to the pharmaceutical compositions containing such compounds as active ingredient. This invention also relates to a method for treating hypertension in hypertensive mammals.

  本发明涉及苯二氧杂基烷基哌啶类化合物，涉及生产这些化合物的方法以及含有这些化合物作为活性成分的药物组合物。本发明还涉及一种治疗高血压的方法，适用于高血压哺乳动物。
• [EN] NOVEL IMMUNE SYSTEM MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU SYSTÈME IMMUNITAIRE
  申请人：JANUS BIOTHERAPEUTICS INC

  公开号：WO2012167046A1

  公开（公告）日：2012-12-06

  The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.

  本发明涉及一种化合物，其化学式为I：或其药用可接受的盐，其中符号如规范中定义；包括相同化合物的药物组合物；以及使用相同化合物治疗或预防自身免疫疾病的方法。